Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast CancerJuly 4th 2020
According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.
Tisotumab Induces Clinically Meaningful, Durable Responses in Recurrent Metastatic Cervical CancerJune 30th 2020
"Available therapies upon progression after first-line chemotherapy in recurrent or metastatic cervical cancer are limited, and there is a significant unmet need for new treatment options."
Diverse Populations Necessitate Innovative Combinations in Ovarian CancerJune 20th 2020
“We are starting to see more and more patients with recurrent ovarian cancer, we’re treating them much more aggressively in the up-front setting, and we have to face PARP inhibitor resistance in the future.”
Camrelizumab/Apatinib Shows Early Activity in Advanced Cervical CancerJune 8th 2020
In the treatment landscape for advanced cervical cancer, no approved options exist for patients after first-line treatment. Based on phase 2 data, camrelizumab plus apatinib is showing promise.
Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian CancerMay 31st 2020
Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Niraparib/Bevacizumab Combo Supported With New Data From the AVANOVA2 StudyMay 30th 2020
Statistically significant improvements in time to second progression or death, or PFS2, was demonstrated in the bevacizumab/niraparib combination, as well as other positive clinical outcomes.
Responses to Olaparib/Cediranib Combination in Ovarian Cancer Warrant Further InvestigationMay 29th 2020
Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.
Personalized Treatment Approaches Improve Outcomes for Patients With Ovarian CancerMay 20th 2020
In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed the importance of molecular testing in ovarian cancer and how the treatment landscape will continue to evolve in tailoring treatment to patients based on the biology of their tumors, which was the topic of his lecture at the 2020 Society for Gynecologic Oncology (SGO) Annual Meeting.
FDA Approves Niraparib As Frontline Maintenance in Advanced Ovarian CancerApril 29th 2020
"This approval is an important step forward in the treatment of ovarian cancer. In my opinion, maintenance treatment with niraparib should be considered an option for appropriate patients who responded to first-line platinum-based chemotherapy versus active surveillance."
Two Analyses Describe Patient Preferences for Maintenance Therapy in Ovarian CancerApril 25th 2020
In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.
Dostarlimab on the Road to Progress in dMMR Endometrial CancerApril 24th 2020
“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”
Novel Monoclonal Antibody Demonstrates Clinical Activity in Gynecologic MalignanciesApril 23rd 2020
"We are seeing clinically meaningful monotherapy activity of DKN-01 in heavily pre-treated endometrial cancer and carcinosarcoma populations, including a complete response, a partial response, and durable tumor reductions in many patients. In combination with paclitaxel, DKN-01 is generating durable responses and disease control in paclitaxel-experienced patients."
FDA Approves cobas HPV Test for Measurement of Cervical Cancer Risk in Women with High-Risk HPVApril 21st 2020
"The approval of our HPV test for the cobas 6800 and 8800 Systems enables molecular laboratories to achieve the efficiency and scale they need to meet the demands of high-volume cervical screening programs..."